
    
      This study is a special drug use surveillance to evaluate the safety and efficacy of Entresto
      Tablets (hereafter called Entresto) clinically administered in Japanese patients for the
      newly approved indication of "chronic heart failure" and to be conducted as one of the
      RMP-specified additional pharmacovigilance activities.
    
  